Advertisement

Chromatographia

, Volume 56, Issue 3–4, pp 237–241 | Cite as

Selective solid phase extraction of a drug lead compound using molecularly imprinted polymers prepared by the target analogue approach

  • B. Dirion
  • F. Lanza
  • B. Sellergren
  • C. Chassaing
  • R. Venn
  • C. Berggren
Short Communication Solid Phase Extraction

Summary

Molecularly imprinted polymers have been evaluated at the sample clean-up stage in the analysis of a drug lead compound. In order to circumvent quantification problems related to bleeding of the template, a structurally related analogue of the latter was used. This was selected based on criteria related to interaction site location, solubility, availability and stability of the analogue. Selection of suitable polymerisation conditions was then made using a small batch format (ca. 50 mg) and rapid assessment of binding in the equilibrium mode. It was found that the amount of template could be greatly reduced compared to the conventional protocol, requiring only 5 μmol of template per gram of polymer without seriously compromising the performance of the materials for chromatographic or SPE applications.

Key words

Solid phase extraction Column liquid chromatography Molecularly imprinted polymers Drug analysis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Sellergren, B. Ed.,Molecularly imprinted Polymers: Man-made mimics of antibodies and their application in analytical chemistry, Elsevier: Amsterdam,2001.Google Scholar
  2. [2]
    Lanza, F.; Hall, A.J.; Sellergren, B.; Bereczki, A.; Horvai, G., Bayoudh, S.; Cormack, P.A.G.; Sherrington, D.C.Anal. Chim. Acta 2001,435, 91–106.CrossRefGoogle Scholar
  3. [3]
    Haupt, K.The Analyst 2001,126, 747–756.CrossRefGoogle Scholar
  4. [4]
    Barceló, D.,Trends Anal. Chem. 1999,18, 137–137.Google Scholar
  5. [5]
    Andersson, L.I.,J. Chromatogr. B 2000,739, 163–173.Google Scholar
  6. [6]
    Olsen, J.; Martin, P.; Wilson, I.D.,Anal. Commun. 1998,35, 13H-14H.CrossRefGoogle Scholar
  7. [7]
    Hennion, M.-C.J. Chromatogr. A 1999,856, 3–54.CrossRefGoogle Scholar
  8. [8]
    Sellergren, B.Trends Anal. Chem. 1997,16, 310–320.CrossRefGoogle Scholar
  9. [9]
    Lanza, F.; Sellergren, B.Anal. Chem. 1999,71, 2092–2096.CrossRefGoogle Scholar
  10. [10]
    Takeuchi, T.; Fukuma, D.; Matsui, J.Anal. Chem. 1999,71, 285–290.CrossRefGoogle Scholar
  11. [11]
    Andersson, L.I.; Paprica, A.; Arvidsson, T.Chromatographia 1997,46, 57–62.CrossRefGoogle Scholar
  12. [12]
    Dauwe, C.; Sellergren, B.J. Chromatogr. A 1996,753, 191–200.CrossRefGoogle Scholar
  13. [13]
    Mayes, A.G.; Lowe, C.R. InDrug development assay approaches including molecular imprinting and biomarkers; Reid, E., Ed.; The Royal Society of Chemistry: Cambridge1998,226, 28.Google Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 2002

Authors and Affiliations

  • B. Dirion
    • 1
  • F. Lanza
    • 1
  • B. Sellergren
    • 1
  • C. Chassaing
    • 2
  • R. Venn
    • 2
  • C. Berggren
    • 3
  1. 1.Institut für Anorganische Chemie und Analytische ChemieJohannes Gutenberg Universität MainzMainzGermany
  2. 2.Bioanalytical Group, Department of Drug MetabolismPfizer Global Research and DevelopmentSandwichUK
  3. 3.MIP Technologies ABLundSweden

Personalised recommendations